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ABSTRACT
Objective: To analyze the epidemiological characteristics 
of adolescents with cancer referred to an oncologic center, 
between 2000 and 2006.
Methods: A retrospective descriptive study was carried 
out in order to evaluate the epidemiological data of patients 
aged between ten and 19 years at diagnosis and admitted 
at the Institute of Oncology (IOP/Graacc) of Universidade 
Federal de São Paulo, Brazil, between 2000 and 2006.
Results: Among 2,362 patients admitted during this pe-
riod with a diagnosis of cancer, 629 (26.6%) were adolescents. 
Mean age was 13.7 years, being 56.8% male. Regarding race, 
60.7% of the patients were white, 30% mulattoes, 6.5% 
blacks, and 2.5% of patients had no characterization of race 
in the medical records. The most frequent types of tumors 
were: central nervous system tumors (22.1%), osteosarcoma 
(14.6%), lymphoma (14.5%), and leukemia (14.5%). The 
overall survival at five years was 73.7%. Adolescents with 
the diagnosis of rhabdomyosarcoma presented disseminated 
disease and histology of worse prognosis, which contributed 
for increasing the mortality rate of this group of patients.
Conclusions: Adolescents with cancer are a group of patients 
with distinct characteristics when compared to other cancer 
groups. Our results show differences in the prevalence of tumors 
during adolescence and childhood, in the later leukemias and 
central nervous system tumors predominate. It is crucial to 
facilitate the access of adolescents to oncologic centers in order 
to provide early diagnosis and proper treatment.
Key-words: adolescent; neoplasm; epidemiology.
RESUMO
Objetivo: Analisar as características epidemiológicas dos 
adolescentes portadores de neoplasias encaminhados para 
o Instituto de Oncologia Pediátrica (IOP/GRAACC) da 
Universidade Federal de São Paulo, entre os anos de 2000 
a 2006.
Métodos: Trata-se de um estudo retrospectivo descritivo, 
em que foram avaliados os dados epidemiológicos dos pacien-
tes, com idade entre dez e19 anos ao diagnóstico, admitidos 
do ano 2000 a 2006 no IOP/Graacc.
Resultados: Do total de 2.362 pacientes admitidos neste 
período com diagnóstico de câncer, 629 (26,6%) eram ado-
lescentes. A idade média encontrada foi de 13,8 anos, sendo a 
maioria do sexo masculino (56,8%). Em relação à raça, 60,7% 
dos pacientes eram brancos. Os tipos de tumores mais frequen-
tes foram: tumores de sistema nervoso central (22,1%), oste-
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ossarcoma (14,6%), linfomas (14,5%) e leucemias (14,5%). 
A sobrevida global, em cinco anos, dos 629 pacientes deste 
estudo foi de 73,7%. Destaca-se que os adolescentes com rab-
domiossarcoma apresentavam doença disseminada e histologia 
de pior prognóstico, contribuindo para o aumento na taxa de 
mortalidade deste grupo de pacientes.
Conclusões: Os adolescentes com câncer correspondem 
a um grupo de pacientes que apresenta características pe-
culiares quando comparado a outros grupos oncológicos. 
Há diferença histológica dos tumores dos adolescentes com 
os da infância, em que predominam leucemias e tumores 
do sistema nervoso central. Nesse contexto, é fundamental 
facilitar o acesso desses pacientes a centros especializados 
e oferecer meios apropriados para o diagnóstico precoce e 
tratamento adequado.
Palavras-chaves: adolescente; neoplasias; epidemiologia.
RESUMEN
Objetivo: Analizar las características epidemiológicas de los 
adolescentes portadores de neoplasias encaminados al Instituto 
de Oncología Pediátrica (IOP/GRAACC) de la Universidad 
Federal de São Paulo, entre los años 2000 a 2006.
Métodos: Se trata de un estudio retrospectivo descriptivo, 
en el que fueron evaluados los datos epidemiológicos de los 
pacientes, con edad entre 10 y 19 años al diagnóstico, admiti-
dos entre los años de 2000 y 2006 en el IOP/GRAACC.
Resultados: Del total de 2.362 pacientes admitidos en 
ese periodo con diagnóstico de cáncer, 629 (26,6%) eran 
adolescentes. El promedio de edad fue de 13,8 años, siendo 
la mayoría del sexo masculino (56,8%). Respecto a la raza, 
60,7% de los pacientes eran blancos. Los tipos de tumores 
más frecuentes fueron: tumores de sistema nervioso central 
(22,1%), osteosarcoma (14,6%), linfomas (14,5%) y leu-
cemias (14,5%). La sobrevida global en cinco años de los 
629 pacientes de este estudio fue de 73,7%. Se subraya que 
los adolescentes con rabdomiosarcoma admitidos al presente 
estudio presentaban enfermedad diseminada e histología 
de peor prognosis, contribuyendo al aumento en la tasa de 
mortalidad de este grupo de pacientes.
Conclusiones: Los adolescentes con cáncer corresponden a 
un grupo de pacientes que presenta características peculiares 
si comparados a otros grupos oncológicos. Hay diferencia his-
tológica de los tumores de los adolescentes con los de la infancia, 
en que predominan leucemias y tumores del sistema nervioso 
central. En ese contexto, es fundamental facilitar el acceso de esos 
pacientes a centros especializados y ofrecer medios apropiados 
al diagnóstico temprano y tratamiento adecuado.
Palabras clave: adolescente; neoplasias; epidemiología.
Introduction
Cancer is a social problem that does not only affect 
the patients themselves, but also impacts on their fami-
lies and  communities. It is rarely diagnosed in adolescence(1) 
and demands careful and complex management by health 
professionals. Despite all of the advances that have been 
achieved in oncology, there are still many questions to be 
answered in relation to cancer in adolescents(2).
Studies of cancer in adolescents are rare and difficult to 
interpret, since epidemiological aspects of cancer in young 
people are very often analyzed in conjunction with data from 
children or adults(2). Adolescents with malignant neoplasms 
have a lower survival rate than other age groups, probably 
because of problems accessing oncology centers and because 
healthcare policies focus on children and adults(2,3). In the 
United States, 94% of cancer patients under the age of 15 
years were put on cooperative protocols at specialized centers, 
whereas only 21% of those aged 15 to 19 were in cooperative 
groups, demonstrating failure to care for adolescents(2).
In Brazil, malignant neoplasms are one of the principal 
causes of deaths among adolescents, although external causes 
(accidents and violence) are even more prevalent in all five 
of the country’s regions. The most common causes of death 
from cancer are malignant neoplasms of lymphatic and he-
matopoietic tissues, accounting for around 50% of cancer 
deaths in the 10–14 years age group and 40% of cancer 
deaths among 15 to 19-year-olds(1).
The objective of this study was to analyze the epide-
miological characteristics of adolescents admitted with 
neoplasms to a pediatric oncology center. The importance 
of this study lies in the need to collect data on cancer in 
adolescents (age, sex, types of tumor and survival rates) in 
order to better understand the incidence and outcomes of 
neoplasms in this special group of patients who have their 
own characteristics and need specialized attention.
Methods
This was a retrospective descriptive study that analyzed 
the medical records from 2000 to 2006 for all patients 
with diagnoses of cancer who were aged 10 to 19 at referral 
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to a single specialist center, the Pediatric Oncology 
Institute’s Adolescent and Child Cancer Support Group 
(IOP/Graacc) at the Universidade Federal de São Paulo 
(Unifesp). The IOP/Graacc is a highly complex center to 
which children and adolescents from all over Brazil are 
referred after being diagnosed with cancer, at a rate of 
300 new cases per year.
Epidemiological data such as age, sex and race were 
recorded, in addition to type of tumor, presence/absence of 
metastasis, clinical stage and survival for the entire sample. 
Secondary neoplasms diagnosed during the period were 
also analyzed. Cases were excluded if the primary tumor 
was diagnosed at an age younger than 10 or older than 19 
years or if the cases were related to relapsed primary tumors 
originally diagnosed before the patient was 10. All patients 
were treated according to the pediatric treatment protocols 
used at the institution during the study period and were 
cared for by a multidisciplinary team.
The statistical analysis was conducted using database 
software (Excel) and statistical programs such as SPSS 11.5. 
Frequencies were analyzed and the Kaplan-Meier method 
was used to analyze outcomes. This study was approved by 
the Research Ethics Committee at Unifesp.
Results
A total of 2,362 patients were admitted between 2000 
to 2006 with cancer diagnoses and 629 (26.6%) of them 
were adolescents.
The adolescents’ mean age was 13.8 years, 59.6% of cases 
were in the 10–14 age group and 40.4% were aged 15 to 19. 
When the different types of neoplasm were stratified by age, 
it was observed that osteosarcomas (bone tumors) and non-
rhabdomyosarcoma soft tissue sarcomas occurred at a higher rate 
in the 15 to 19 age group; rhabdomyosarcoma soft tissue tumors 
were evenly distributed by age; and all other types of tumor had 
higher incidence from 10 to 14 years of age (Figure 1).
With regard to sex distribution, 357 (56.8%) of the sample 
were male and 272 (43.2%) were female. There was a greater 
incidence of the principal tumor types among males. With 
regard to skin color/race, 60.7% of the patients studied were 
white, 30.0% had brown skin, 6.5% were black and 2.5% of 
patients’ medical race did not contain any indication of race.
The principal tumor types observed in these adolescents, 
by order of frequency, were as follows: tumors of the central 
nervous system (CNS) (22.1%), osteosarcomas (14.6%), 
lymphomas (14.5%), leukemias (14.3%), Ewing family 
Figure 1 - Relationship between age group and neoplasm type 
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tumors/primitive neuroectodermal tumors (PNET); (7.1%), 
germ cell tumors (5.9%), non-rhabdomyosarcoma sarcomas 
(5.6%), carcinomas (4.6%) and others.
In this study, CNS tumors were the most common type 
of cancer, accounting for 22.1% (139/629) of cases. The 
most common subtypes of CNS tumor were: astrocytomas 
38.8% (54/139), medulloblastomas 15.8% (22/139), cranio-
pharyngiomas 15.1% (21/139) and germ cell tumors 11.5% 
(16/139). The majority of CNS tumors had onset when 
patients were between 10 and 14 years old (69.1% of cases). 
Males accounted for 61.8% of CNS tumor cases.
There was a greater number of malignant bone tumors 
than benign ones (137 cases – 87.8%) and osteosarcoma was 
the most common type of malignant bone tumor (92/137 
– 67.1%). Osteosarcoma patients were evenly distributed 
across the two age groups, with 47.8% in the 10 to 14 age 
group and 52.2% in the 15 to 19 group, and 59.8% of 
patients with this type of bone tumor were male. The most 
common osteosarcoma sites were: femur (46.7%), tibia 
(23.9%) and humerus (9.8%). Pulmonary metastasis was 
detected in 37.8% of these patients at the time of diagnosis. 
Ewing’s sarcomas accounted for 32.8% (45/137) of bone 
tumors, 55.6% of these cases were in the 10 to 14 age group 
and more females were affected than males (53.3%). The pel-
vis was the primary site of 26.7% of Ewing’s sarcoma cases, 
with 22.2% in the femur, 13.3% in the tibia and 37.8% in 
other sites (Figure 2). At the time of diagnosis, pulmonary 
metastasis incidence among patients with Ewing’s sarcoma 
was already at 35.6%.
In this study, 14.4% of cases were lymphomas (91/629), 
63.7% of which were Hodgkin’s lymphomas (HL) and 36.3% 
non-Hodgkin’s lymphomas (NHL). It was observed that 
55.2% of the 58 cases of HL were in the 15 to 19 age group, 
56.9% were male and 56.9% were initially staged at I/II. The 
10 to 14 age group contained 63.6% of the 33 cases of NHL 
and NHL incidence was greater among males (60.6%). The 
NHLs were diagnosed at advanced stages: 80.6% of cases were 
stage III/IV, while 19.4% were stage I/II (Figure 3).
There were 90 cases of leukemia among the adolescents: 
61.1% were acute lymphoid leukemia (ALL), 31.1% were 
acute myeloid leukemia (AML) and 7.8% were chronic 
myeloid leukemia (CML). Among the adolescents with 
ALL, 78.2% were aged 10 to 14 years and 58.2% were 
male; 71.4% of the AML patients were aged 10 to 14 years 
and 53.6% were female whereas all of the CML cases were 
detected at ages between 10 and 14 and 85.7% of these 
patients were male.
Projected global 5-year survival, estimated by 
Kaplan-Meier survival analysis of all 629 patients in 
the study, was 73.74% (Figure 4).
Discussion
Incidence of malignant neoplasms increases gradually 
after 10 years of age. Cancer diagnosis rates are around three 
times greater after the age of 15 than before this age(3). In 
this study, 26.6% (629/2362) of the patients admitted to 
our referral center were adolescents. This could be an un-
derestimation, however, since only one third of adolescents 
with cancer get to pediatric oncology centers(2).
Figure 2 - Relationships between primary site and bone 
tumor type 
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Lymphomas are the most frequent malignant tumors among 
adolescents, followed by leukemias, CNS tumors and bone 
tumors(3-5). The most common types of tumor found in our pa-
tients were as follows: CNS tumors, bone tumors, lymphomas 
and leukemias. It was to be expected that our results would 
diverge from the literature, since this study was conducted at 
a specialist CNS and bone tumor treatment center.
Our sample of adolescents was 56.8% male (357). Data 
on the relationship between tumor incidence and sex in 
this age group are divergent, but males seem to be affected 
more often(6-8).
Epidemiological studies have shown that among adolescents 
cancer is 50% more common in the 15 to 19 year age group 
than among 10 to 15-year-olds, with 203 new cases per million 
people(9-11). However, the average age observed in this study was 
13.7 years and just 40.4% of the adolescents were aged 15 to 19. 
This divergence from published data is probably because the study 
was conducted at a single pediatric institution and therefore suf-
fers from bias introduced by sampling only patients referred to 
the oncology center in question.
When associations between neoplasm type and age were 
analyzed, it was observed that osteosarcomas and non-
rhabdomyosarcoma sarcomas were the only tumor types that 
occurred with greater frequency in the 15 to 19 age group, 
which was expected since this class of tumors has greater 
incidence among adolescents and young adults.
Figure 4 - Global 5-year survival of the 629 adolescents 
with cancer
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1.0 In Brazil, analysis of the incidence of tumors with relation 
to race can be subject to an important bias resulting from 
racial admixture and data harvested from medical records are 
subject to the subjectivity of those responsible for completing 
them. Despite this, the findings of our study are comparable 
with the literature, since 60.7% of the patients studied were 
white. Studies have shown that there is a clear difference be-
tween whites and blacks in terms of the incidence of tumors; 
in general whites have higher incidence rates(5,12).
In our study CNS tumors were the most common cancer 
type, accounting for 22.1% (139/629) of cases. Central nervous 
system tumors primarily affected males at ages from 10 to 14 
years, which is in line with the literature(7). Central nervous 
system tumors include benign and malignant tumors and are an 
important class of tumors among adolescents(13). In the United 
States, CNS tumors are the second most common pediatric 
tumor(13) and the seventh most common tumor type among 
people 15 to 29 years old(7). These tumors and their treatments 
are responsible for significant morbidity, including physical de-
ficiencies and neuropsychological and neuroendocrine sequelae. 
They are also one of the principle causes of cancer mortality 
among the pediatric population and young adults.
Onset of bone tumors is associated with periods in which 
there is rapid bone growth, such as in adolescence. The signs 
and symptoms of these tumors, such as pain and localized 
swelling can be confused with traumas, delaying diagnosis. In 
the United States, malignant bone tumors have an annual in-
cidence of 8.7 cases per million children and adolescents under 
20(8,13,14). Peak incidence of malignant primary bone tumors is 
during the second decade of life and among adolescents 95% 
of these tumors are osteosarcomas or Ewing’s sarcomas(2,11). 
Osteosarcomas were the most common bone tumor type 
in our sample (67.2%) and were evenly distributed by age 
(47.8% were in the 10 to 14 age group). Osteosarcomas are 
generally located in the metaphyseal regions of long bones; 
the distal femur, proximal tibia and proximal humerus. This 
type of tumor is also generally linked with a high degree of 
malignity and a high rate of metastasis, particularly in the 
lungs. According to observations described in the literature, 
metastases are detected in 15 to 21% of patients, impacting 
on prognosis(15-20). The presence of metastasis is considered the 
worst prognostic factor and after both univariate and multi-
variate analyses less than 20% of such patients achieve 5-year 
disease-free survival(18). In our study, 37.8% of these patients 
had pulmonary metastases on diagnosis. This percentage is 
higher than reports in the literature and may be related to late 
diagnosis, which makes it more likely that the disease will 
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have progressed to more advanced stages. The importance 
of early diagnosis means that when faced with nonspecific 
initial symptoms, very often related to traumas, pediatricians 
should be alert to the possibility of neoplasms in children and 
adolescents with symptoms of persistent bone pain, associated 
with trauma, and should investigate without delay.
Ewing’s sarcomas are the second most common malignant 
primary neoplasm of the bones and primarily affects patients 
aged 10 to 30(13). According to a study published by the 
European Intergroup Cooperative Ewing’s Sarcoma Study 
(EICESS), 56% of a total of 1,426 patients studied were 
diagnosed at ages between 10 and 20 and 44% of these were 
over 15. In our study 55.6% of Ewing’s sarcoma patients were 
aged from 10 to 14, probably because the oncology center in 
question is a pediatric institution. In contrast with the osteo-
sarcomas, incidence was higher among females, at 53.3% of 
cases. This type of tumor has a greater preference for flat bones 
than osteosarcomas. The incidence of pulmonary metastases 
among Ewing’s sarcoma patients at the time of diagnosis was 
similar to that for osteosarcomas, at 35.6% of cases. According 
to the literature, approximately 25% of patients with Ewing’s 
sarcoma have pulmonary metastasis on diagnosis and this is 
generally associated with late diagnosis and poor prognosis(21), 
demonstrating the importance of early diagnosis. These data 
should serve to highlight certain facts: the center analyzed 
here is an institution that receives patients from all over 
Brazil, probably very often months late; probably due to the 
facts that Ewing’s sarcoma is a rare disease with nonspecific 
initial signs and symptoms and this is an extremely active 
age group leading to this clinical presentation being under-
valued. Irrespective of this, the question remains of whether 
the increased incidence of pulmonary metastases at the time 
of diagnosis of bone tumors that is observed in Brazil could 
have a link to some difference in tumor biology.
Lymphomas are malignant neoplasms of the lymphoid 
system which can be related to autoimmune, infectious and 
immunosuppressive causes. The incidence of Hodgkin’s 
lymphomas (HL) in adolescents aged 15 to 19 is around 
twice that of non-Hodgkin’s lymphomas (NHL)(22). In our 
study, 55.2% of patients with HL had onset at 15 to 19 years 
of age. In contrast, 63.6% of NHL cases occurred between 
10 and 14, confirming findings reported in the literature. 
It should be pointed out that after diagnosis, in addition to 
classifying the disease by lymphoma type, it is also important 
to determine the stage since these data are indispensable to 
selecting the correct treatment for each patient and estimat-
ing their prognosis. In our study, 56.9% of HL cases had 
initial staging of I or II at diagnosis. In contrast, NHL cases 
were diagnosed at more advanced stages, to the extent that 
at diagnosis 80.6% of cases were staged at III or IV, which 
is due to the rapid growth of this type of tumor.
Leukemias account for around one third of malignant neo-
plasms in children and one seventh of tumors in adolescents(2). 
In our study sample there were 90 leukemia cases in adolescents, 
61.1% of them were ALL, 31.1% AML and 7.8% were CML. 
The incidence of these leukemia subtypes is similar to what is 
seen in the pediatric age group and contrasts with the picture 
in adults, among whom the most frequent type is CML(23,24). In 
the United States, approximately 6,500 children and adolescents 
under 20 develop acute leukemia each year(23,24). Of the adoles-
cents with ALL in our sample, 78.2% of cases were diagnosed 
in patients aged 10 to 14, with higher incidence among males 
(58.2%), which is in line with the literature(13,23). Acute myeloid 
leukemia incidence is uniform among children, but there is a 
discrete increase during adolescence(13). Chronic leukemias are 
rare both in childhood and in adolescence. The most common 
chronic form that affects this population is CML, which accounts 
for less than 5% of all leukemias in this age group, equating to 
approximately one hundred cases per year in the United States 
pediatric population(23,24). Chronic myeloid leukemia is primarily 
diagnosed in people between 30 and 50 years old(24). Just 7.8% of 
all leukemias diagnosed among the adolescents studied here were 
CML and all of these cases were diagnosed at ages from 10 to 14. 
No significant differences have been reported in the sex or race 
distribution of this disease(24). In contrast, even though the small 
sample size affects the significance of the finding, CML incidence 
was greater among males, with 85.7% of cases.
Interpretation of different survival rates between age groups 
is complicated by obstacles such as histological typing, initial 
staging and follow-up period. Adolescents with leukemia put 
on pediatric protocols have exhibited better survival rates(25). 
In contrast, adolescents with tumors that are more common 
among adults, such as melanoma and thyroid cancer, are better 
treated at adult oncology centers. More than 80% of cancer 
mortality in the 15 to 19 age group is the result of four groups 
of malignant tumors: leukemias/lymphomas, sarcomas, CNS 
tumors and germ cell tumors. Among the tumors, leukemia 
is the principal cause of death in the same age group(12,13). 
Overall mortality for all cases described here was 28.5% 
(182/637). In general, for all types of tumor, less than half 
of cases result in death, with the exception of rhabdomyosar-
coma, which caused elevated mortality (66.7%). It is likely 
that these findings are related to the fact that the adolescents 
with rhabdomyosarcoma enrolled on this study already had 
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disseminated disease and alveolar histology indicative of poor 
prognosis at the time of diagnosis. In our sample, the tumor 
types that resulted in the largest proportions of deaths were 
rhabdomyosarcoma (12/18), bone tumors (45/82), leukemias 
(34/56) and CNS tumors (30/109).
With relation to global 5-year survival, studies report 
values of 72% survival for all types of tumor in all pediatric 
age groups(6). Kaplan-Meier analysis estimated the global 
5-year survival of the 629 patients in this study at 73.7%, 
which is similar to what is found in the literature, where 
global survival is 72% at 5 years(6).
With reference to the results of this study, it can be con-
cluded that adolescents with cancer are a group that merits 
interest, both because of the incidence and because of their 
special care requirements, since this group has significant dif-
ferences in terms of the classification and biological behavior 
of tumors and there are also differences in terms of clinical 
presentation, treatment, support and prognosis. Therefore, 
early diagnosis and access to specialized pediatric or adult 
oncology centers should be facilitated; while oncology cen-
ters must equip themselves to cater for the specific needs of 
this group of patients, in order to be in a position to offer 
adequate support and treatment. Finally, it should be pointed 
out that this study was conducted at a specialist referral cen-
ter and cooperative multicenter studies are needed to validate 
the results on a national and international scale.
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